A major breakthrough in tuberculosis treatment is on the horizon: next-generation TB vaccines expected to roll out from 2029 could save an estimated 7.3 million lives by 2050.

Beyond the lifesaving potential, these "blockbuster" vaccines promise to generate up to US$135 billion in economic benefits for low- and middle-income countries while simultaneously supporting global efforts to combat antimicrobial resistance—a growing health crisis. Experts emphasize that action must be taken now to ensure these life-changing vaccines reach the countries that need them most. Read the full story →

Today's takeaway: When innovation meets public health planning, the results can be transformative—potentially saving millions of lives while strengthening economies worldwide.